 |
| Company |
Product name
/number |
Product
type |
Phase of development |
Status and
comment
(October 1997) |
| PC |
I |
II |
III |
L |
|
| AstraZeneco |
Clomethiazole |
Enhancer of GABAa receptor
activity |
 |
 |
 |
 |
|
Under development in large
ischaemic infarcts |
| AR-r15896AR |
NMDA antagonist |
|
|
|
|
|
A low affinity, use-dependent
agent |
| NXY-059 |
Free radical trapping
agent |
|
|
|
|
|
|
| Pre-clinical leads |
Nitric oxide inhibition |
|
|
|
|
|
|
|
| BASF Pharma |
Ancrod |
Clot-dissolving snake
enzyme |
|
|
|
|
|
Isolated from the Malayan
pit viper |
|
| Bayer |
X3702 |
Serotonin receptor stimulator |
|
|
|
|
|
Also has anti-anxiety
and anti-depressant properties |
|
| Boehringer-Ingelheim |
Alterplase |
Genitically engineered
tPA |
|
|
|
|
|
|
| Dipyridamole |
Anti-platelet agent |
|
|
|
|
 |
|
| Aspirin + Dipyridamole |
Anti-platelet |
|
|
|
|
|
|
|
| Bristol-Myers Squibb |
Pravastatin |
Lipid Lowering 'statin' |
|
|
|
|
|
The only 'statin' so far
licensed in the UK for stroke prvention |
| Clopidogrel |
Anti-platelet agent |
|
|
|
|
|
Co-marketed with Sanofi-Winthrop |
|
| British Biotech |
BB10153 |
Genetically engineered
plasminogen |
|
|
|
|
|
|
|
| Cerebrus |
Pre-clinical leads |
Sodium channel blockers |
|
|
|
|
|
A novel mechanism for
neuroprotection |
|
| Eisai |
Satigrel (E5510) |
Anti-platelet agent |
|
|
|
|
|
|
|
| Eli Lilly & Company |
Abciximab |
Anti body that blocks
platelet GPIIb/IIIa receptors |
|
|
|
|
|
Available for prevention
of clots in cardiac surgery |
|
| Glaxo Wellcome |
GV 150526 |
Glycine antagonist |
|
|
|
|
|
|
|
| Hoechst Marion Roussel |
Streptokinase |
Triggers fibrinolysis |
|
|
|
|
|
For other thromboembolic
disorders |
|
| Leo Pharmaceuticals |
Urokinase |
Plasmingen activator |
|
|
|
|
|
At trial stage only for
stroke. For other thromboembolic disorders |
|
| Merck Sharp & Dolme |
Simvastatin |
Lipid lowering 'statin' |
|
|
|
|
|
Under investigation for
stroke. Available for high cholesterol and coronary heart
disease |
| Tirofiban |
Platelet GPIIb/IIIa receptor
blocker |
|
|
|
|
|
|
|
| Organon |
Danaparoid |
Related to heparin |
|
|
|
|
|
|
|
| Pfizer |
Neutrophil Inhibitory
Factor(NIF) |
Recombinat hookworm factor |
|
|
|
|
|
Isolated from the canine
hookworm |
|
| Pharmacia & Upjohn |
Tirilazad mesylate |
Oxygen free-radical scavenger |
|
|
|
|
|
Licensed in Europe but
not the UK for sub-arachnoid haemorrhage |
| Streptokinase |
Triggers fibrinolysis |
|
|
|
|
|
At trial stage only for
stroke. For other thromoembolic disorders |
|
| Sanofi Winthrop |
Clopidogrel |
Anti-platelet agent |
|
|
|
|
|
Co-marketed with Bristol
Myers Squibb |
|
| Schering-Plough |
Eptifibatide |
Cyclic peptide platelet
GPIIb/IIIa blocker |
|
|
|
|
|
|
|
| Searle |
Xemilofiban |
Blocks platelet GPIIB/IIIa
receptors |
|
|
|
|
|
|
|
| Serono |
Urokinase |
Plasminogen activator |
|
|
|
|
|
At trial stage only for
stroke. For other thromboembolic disorders |
|
| SmithKline-Beecham |
Lotrafiban |
Non-peptide platelet GPIIb/IIIa
blocker |
|
|
|
|
|
Orally active |
|
| Yamanouchi |
YM872 |
AMPA receptor antagonist |
|
|
|
|
|
|
|
